HLS Therapeutics Inc. (FRA:74D)

Market Cap	85.71M +6.6%
Revenue (ttm)	47.27M -2.0%
Net Income	-10.59M
EPS	-0.34
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	2.540
Previous Close	2.580
Day's Range	2.540 - 2.620
52-Week Range	2.340 - 3.420
Beta	n/a
RSI	51.26
Earnings Date	Mar 12, 2026

About HLS Therapeutics

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovas...

• Industry: Pharmaceutical Preparations
• CEO: Craig Millian
• Employees: 85
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 74D

Financial Performance

In 2025, HLS Therapeutics's revenue was $55.50 million, a decrease of -1.98% compared to the previous year's $56.62 million. Losses were -$12.43 million, -36.76% less than in 2024.

Financial numbers in USD